- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | Why Is PepGen Stock Sinking Tuesday? | 2 | Benzinga.com | ||
| 31.03. | PepGen crashes after mid-stage trial data for muscle disorder therapy | 1 | Seeking Alpha | ||
| 30.03. | PepGen-Aktie stürzt nach enttäuschenden Studiendaten um 44 % ab | 7 | Investing.com Deutsch | ||
| 30.03. | PepGen Inc. - 8-K, Current Report | - | SEC Filings | ||
| PEPGEN Aktie jetzt für 0€ handeln | |||||
| 30.03. | PepGen reports mixed results from DM1 trial, 10mg cohort ongoing | 1 | Investing.com | ||
| 05.03. | PepGen muscular dystrophy drug gets 'surprise' hold from FDA | 2 | BioPharma Dive | ||
| 05.03. | Stifel reiterates Buy on PepGen stock amid partial clinical hold | 6 | Investing.com | ||
| 05.03. | PepGen slumps as FDA places hold on lead drug | 1 | pharmaphorum | ||
| 05.03. | PepGen slides on FDA partial hold on mid-stage trial for lead asset | 1 | Seeking Alpha | ||
| 05.03. | PepGen hit with partial clinical hold, analysts blame 'understaffed FDA' | 2 | FierceBiotech | ||
| 05.03. | FDA Places Partial Hold On PepGen's Myotonic Dystrophy Drug Trial | 1 | Benzinga.com | ||
| 05.03. | PepGen GAAP EPS of -$0.27 beats by $0.12 | 1 | Seeking Alpha | ||
| 04.03. | FDA verhängt teilweisen klinischen Stopp für PepGen-Studie zu myotoner Dystrophie | 6 | Investing.com Deutsch | ||
| 04.03. | PepGen Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 04.03. | PepGen Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 04.03. | PepGen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.02. | Guggenheim raises PepGen stock price target to $7 on trial outlook | 2 | Investing.com | ||
| 08.12.25 | PepGen appoints Joseph Vittiglio as chief business and legal officer | 13 | Investing.com | ||
| 08.12.25 | PepGen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | PepGen GAAP EPS of -$0.52 | 1 | Seeking Alpha |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,55 | +1,58 % | BioNTech SE: BioNTechs und DualityBios Antikörper-Wirkstoff-Konjugat-Kandidat Trastuzumab Pamirtecan zeigte klinisch relevante Wirksamkeit bei Patientinnen mit rezidivierendem HER2-exprimierendem Gebärmutterkrebs | Trastuzumab Pamirtecan, ein innovativer gegen HER2 gerichteter Antikörper-Wirkstoff-Konjugat-Kandidat, erreichte den primären Wirksamkeitsendpunkt in einer Phase-2-Kohorte bei stark vorbehandelten Patientinnen... ► Artikel lesen | |
| AMGEN | 296,60 | -0,29 % | BeOne wins China approval for Amgen's lung cancer drug Imdelltra | ||
| NOVAVAX | 7,100 | +3,05 % | Activist investor revives campaign to overhaul Novavax board | ||
| BIOGEN | 151,98 | +1,29 % | Piper Sandler upgrades Biogen stock rating on acquisition strength | ||
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,940 | +0,97 % | What's Going On With Inovio Pharmaceuticals Stock On Tuesday? | ||
| BIONXT SOLUTIONS | 0,306 | +2,68 % | BioNxt sichert sich einheitliches europäisches Patent für seine sublinguale Cladribin-ODF-Plattform in 18 Ländern | VANCOUVER, BC / ACCESS Newswire / 7. April 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FWB:BXT), ein innovatives Biowissenschaftsunternehmen, das
sich... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,150 | +1,17 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| MAINZ BIOMED | 0,607 | +20,07 % | Mainz Biomed BV: EPS übertrifft Schätzungen um 1,11 $ - Umsatz schlechter als erwartet | ||
| INTELLIA THERAPEUTICS | 12,520 | +3,30 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| TEMPUS AI | 41,850 | +7,05 % | Tempus AI Expands Collaboration With Gilead Sciences To Maximize Insights In Oncology Pipeline | FOSTER CITY (dpa-AFX) - Healthcare technology company Tempus AI, Inc. (TEM) Thursday announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (GILD) to build and advance its... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,360 | 0,00 % | Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference | Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference
Halle (Saale) / Munich, Germany, April 9, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon),... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,048 | +0,52 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 46,520 | 0,00 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,740 | +1,30 % | Johnson Fistel, PLLP: Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty | San Diego, California--(Newsfile Corp. - January 12, 2026) - Shareholder rights law firm Johnson Fistel, PLLP is investigating potential shareholder derivative claims on behalf of Sarepta Therapeutics... ► Artikel lesen |
PEPGEN INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,700 Euro und damit +0,59 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PEPGEN INC finden Sie auf Wallstreet Online.